Three-body problem

GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

Retrieved on:

Thursday, April 4, 2024

Health, Neurology, Genetics, Pharmaceutical, Optical, Biotechnology, PIII, URD, Three-body problem, Patient, Good manufacturing practice, Health care, EAP, Acquisition, EMA, Risk, Chapter, GMP, MHRA, DS, ATU, AMF, Good, Phase, AAP, Ethics, FDA, Amendment, AAC, Medication, Pharmaceutical industry

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.

Key Points:

GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of March 31, 2024 and provided a business update.
Once the AAC/AAP program resumes, the Company estimates that the cash runway would be extended to the end of Q1 2025.
GenSight successfully manufactured two Drug Substance (DS) batches of LUMEVOQ® meeting Good Manufacturing Practice (GMP) standards in September and November 2023.
As of March 31, 2024, GenSight Biologics’ number of outstanding shares was 78,370,724 ordinary shares.

GenSight Biologics Reports Full Year 2023 Consolidated Financial Results

Retrieved on:

Friday, March 22, 2024

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.

Key Points:

From 2022 to 2023, the Company's research and development expenses remained stable, at €19.3 million in 2022 and €19.4 million in 2023.
The Company's general and administrative expenses also remained stable and amounted to €5.4 million in 2022 and 2023.
The weighted average number of shares outstanding increased from 46.3 million in 2022 to 48.3 million in 2023, thereby reducing the loss per share from (€0.54) in 2023 to (€0.60) in 2023.
GenSight Biologics will report its cash position as of March 31, 2024 on April 4 2024.

Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference

Retrieved on:

Monday, March 11, 2024

BRISBANE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases and their substrates, a new class of enzymes discovered in-house that are implicated in a broad variety of diseases, today announced an abstract titled “Unveiling of a Novel Therapeutic Antibody Targeting Nitrated Alpha Synuclein for the Treatment of Parkinson’s Disease” was featured in an oral presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conference taking place in Lisbon, Portugal from March 5-9, 2024. The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies. Nitrase’s antibody demonstrated both high affinity and selectivity for nitrated synuclein, and it demonstrated the ability to significantly reduce PD progression in in vitro and in vivo PD models.

Key Points:

The presentation outlined data with Nitrase’s first-in-class antibody targeting extracellular nitrated alpha-synuclein (α-synuclein) for the treatment of Parkinson’s disease (PD) and other synucleinopathies.
A hallmark of PD pathology is the presence of Lewy Bodies and Lewy Neurites, which have been found to include an accumulation of nitrated α-synuclein.
It has been established in published studies that PD pathology spreads between brain regions along neural circuitry through extracellular aggregated α-synuclein.
Additionally, our antibody demonstrated superiority in a preclinical efficacy evaluation against the parental antibody of prasinezumab, which targets non-nitrated α-synuclein.

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on:

Thursday, February 22, 2024

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points:

In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

EudraVigilance - EVWEB user manual

Retrieved on:

Sunday, March 10, 2024

International Organization (journal), Level 2, Automation, Chapter Two, ACK, ISO, Classification, SSL, Sender, Clinical trial, Radio, Immediate, European, CAPS, European Medicines Agency, Report, MDN, ICH, Medicine, HTML, Internet, Medical dictionary, NCA, Originality, HTTPS, SHTTP, European Economic Area, Headquarters, NASK, Three-body problem, Privacy, Match, Database, Data entry, European Economic Community, MSSO, Module, ZIP, Acknowledgment, Acronym, Environment, Message, MLM, Access, Conference, Pharmacovigilance, XML, EMA, Gateway, Chapter One, MedDRA, Active ingredient, Communication, Validation, Public, Data analysis, Precision, RTF, Navigation, Salt, Security, Chapter Five, Contextual, International organization, Convention, SME, URL, Chapter Four, ID, MAH, Rich Text Format, Microsoft Edge, EudraVigilance, Name, MSK, UNK, Risk, Create, Tree view, ICSR, Chapter Three, Web browser, Commercial, R2, Socs, TAB, Literature, Courier, CIOMS, EV, Built-in self-test, Documentation, Coreidae, Council, S-HTTP, File Explorer, UI, Import, Calendar, WEB, Reproduction, Jousting, PDF, Economic union, Mobile phone

Key Points:

Netflix debuts highly anticipated sci-fi series "The Three-Body Problem" at SXSW

Retrieved on:

Saturday, March 9, 2024

Universe, SXSW, Netflix, Television, Multimedia, IPS, Three-body problem, Three body, Sophon, IMDb, Game of Thrones, Hugo Award, IP, Heart, Imagination, The New York Times, Science, Human, Entertainment

Echoing the experience of characters in the series, viewers watched as the mysterious Sophon, an avatar that appears in the show, spoke from the sky.

Key Points:

Echoing the experience of characters in the series, viewers watched as the mysterious Sophon, an avatar that appears in the show, spoke from the sky.
The enduring allure of "The Three-Body Problem" underscores the fundamental questions about existence and inquiries into the human condition.
The entire eight-episode season of Netflix's "The Three-Body Problem" series will officially premiere on the platform on March 21.
Netflix previously released three trailers for the new series, each of which has garnered over ten million views on YouTube.

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

Retrieved on:

Tuesday, March 5, 2024

SCOTTSDALE, Ariz.., March 5, 2024 /PRNewswire/ -- CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and associated biomarker services, today will unveil its NerValence pathology detection system at the AD/PD 2024 conference in Lisbon, Portugal. NerValence, developed through a strategic collaboration with precision pathology company Visiopharm, significantly enhances CND's biomarker testing services for clinical trials targeting the alpha-synuclein protein in patients with suspected Parkinson's disease, dementia with Lewy bodies, and related disorders.

Key Points:

NerValence aids in the identification, tracking, and measuring the volume of alpha-synuclein in cutaneous nerves.
NerValence features machine learning algorithms that recognize and differentiate microscopic structures, nerves, and important disease markers that can be found in cutaneous tissue.
"Utilizing our novel deep learning technology to power this crucial advancement in neurodegenerative diseases represents a significant leap forward in analyzing peripheral nerves," said Michael Grunkin , Visiopharm Chief Executive Officer.
"Collaborating with CND Life Sciences on its deployment of NerValence will continue to be a major priority as we advance AI-driven precision pathology to enhance biopharmaceutical drug development."

AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device

Retrieved on:

Thursday, January 25, 2024

Patient, Incisional hernia, General surgery, Abdominal wall, Medicine, Risk, Quality of life, Disease, Food, FDA, Three-body problem, Laparotomy

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.

Key Points:

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device.
REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia.
Since the first documented laparotomy in 1809, general surgery has been challenged by its limitations in reliably managing a basic but fundamental aspect of abdominal surgery – closure of the abdominal wall.
The impact of a failed abdominal closure can be devastating, with lifelong debilitation, morbidity, and re-operation occurring in a large percentage of patients.

Creating a New Benchmark for Long-duration Lithium Battery Energy Storage -- Global Debut of EVE Energy's Mr. Flagship Series

Retrieved on:

Friday, January 26, 2024

EVE Energy unveiled its CTT technology as early as October 2022 and is one of the pioneering |in the field of long-duration lithium battery energy storage.

Key Points:

EVE Energy unveiled its CTT technology as early as October 2022 and is one of the pioneering |in the field of long-duration lithium battery energy storage.
On January 25, 2024, EVE Energy held an online release conference for its Mr. Flagship Series with the theme "Reliable Energy Storage with EVE Energy's Big Batteries", unveiling its Mr. Big battery cell and Mr.
Build the core essence of "Reliable Energy Storage with EVE Energy's Big Batteries" to lead the world into the era of large-scale energy storage.
As the first company to introduce and achieve swift mass production of the Mr. Flagship Series, EVE Energy has experienced a substantial leap in energy storage battery technology.

Creating a New Benchmark for Long-duration Lithium Battery Energy Storage -- Global Debut of EVE Energy's Mr. Flagship Series

Retrieved on:

Friday, January 26, 2024

EVE Energy unveiled its CTT technology as early as October 2022 and is one of the pioneering |in the field of long-duration lithium battery energy storage.

Key Points:

EVE Energy unveiled its CTT technology as early as October 2022 and is one of the pioneering |in the field of long-duration lithium battery energy storage.
On January 25, 2024, EVE Energy held an online release conference for its Mr. Flagship Series with the theme "Reliable Energy Storage with EVE Energy's Big Batteries", unveiling its Mr. Big battery cell and Mr.
Build the core essence of "Reliable Energy Storage with EVE Energy's Big Batteries" to lead the world into the era of large-scale energy storage.
As the first company to introduce and achieve swift mass production of the Mr. Flagship Series, EVE Energy has experienced a substantial leap in energy storage battery technology.